ArticleBiosensors2026
In Silico Optimization of a Non-Invasive Optical Sensor for Hemoconcentration Monitoring in Dengue Fever Management.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Severe Dengue fever can cause Dengue Hemorrhagic Fever (DHF), a life-threatening condition characterized by plasma leakage and hemoconcentration. A hematocrit (Hct) rise of ≥20% is a key indicator for medical intervention, but current monitoring is invasive and intermittent. This study aims to determine the optimal design parameters for a non-invasive optical sensor to continuously monitor hemoconcentration. We developed a high-fidelity Monte Carlo model of light transport in a multi-layered skin model, with the epidermis set to a 5% melanin volume fraction (Fitzpatrick type II/III). To ensure signal reliability, simulations were conducted with a high photon count (1×108 photons), yielding a stochastic (Monte Carlo) signal-to-noise ratio of approximately 36 dB. We simulated diffuse reflectance at four characteristic wavelengths (577 nm, 660 nm, 800 nm-the isosbestic point-, and 940 nm) over source-detector separations of 0.5-8.0 mm. Sensor sensitivity was quantified as the reflectance change for a +25% relative Hct rise (e.g., 42% to 52.5%), mimicking severe hemoconcentration, and its dependence on baseline dermal blood volume fraction (BVF) was investigated. Sensor sensitivity showed a non-linear dependence on BVF, showing a direct correlation with perfusion level, reaching an optimal 6.41% for a robust 5% BVF at 8.0 mm. A dedicated sweep showed that even under low-perfusion shock conditions (1% BVF), the sensor maintains a highly significant sensitivity of 5.71% (also at 8.0 mm), indicating that sensitivity remains high across a physiologically relevant perfusion range. In the analysis, at a robust 5% BVF, the 800 nm wavelength demonstrated superior reliability, with peak sensitivity at 6.41% at 8.0 mm. Visible wavelengths (577 nm and 660 nm) exhibited high theoretical sensitivity, while 940 nm was compromised by water absorption. Based on these findings, a non-invasive optical sensor for hemoconcentration is most effective operating at 800 nm, within the evaluated spectral set, with a source-detector separation of ≥6.0 mm, targeting the deep dermis while minimizing superficial interference. This design provides an optimal balance of tissue penetration, robust sensitivity to Hct changes, and reduced sensitivity to oxygenation-related variability while maintaining signal stability. This work enables the design of a device for continuous monitoring, supporting continuous monitoring of hemoconcentration trends relevant to plasma leakage progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.